ReviewInnovations in clinical neuroscience
A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis.
Review in Innovations in clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.British journal of clinical pharmacology · 2026Review
- Cannabis, psychosis, and violence: case reports and comprehensive evidence review.Frontiers in psychiatry · 2026Article
- Psychosis and suicide attempt following a single use of delta-9-tetrahydrocannabiphorol: A case report.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics.Scientific reports · 2024Article
- Understanding translational research in schizophrenia: A novel insight into animal models.Molecular biology reports · 2023Review
- Perturbation of 3D nuclear architecture, epigenomic dysregulation and aging, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 1-aging and epigenomics.Frontiers in psychiatry · 2023Review
- Epigenomic and Other Evidence for Cannabis-Induced Aging Contextualized in a Synthetic Epidemiologic Overview of Cannabinoid-Related Teratogenesis and Cannabinoid-Related Carcinogenesis.International journal of environmental research and public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Observations regarding psychostimulant and psychedelic drug-induced psychotic states led to the dopamine, serotonin, and glutamate hypotheses of schizophrenia. Expanding knowledge about the endocannabinoid system and the impact of exogenous cannabinoids on the brain and behavior have elucidated several putative pathways to cannabis-induced psychosis. Objective: The purpose of the present article was to describe these pathways and propose a cannabinoid hypothesis of schizophrenia. Main points: The endocannabinoid system was reviewed. Evidence regarding the effect of delta 9-tetrahydrocannabinol (THC) on the brain was described. A connection between cannabis use and first-episode psychosis was elucidated. Conclusion: Understanding the putative pathways to cannabis-induced psychosis might lead to targeted therapeutic interventions and prevention of schizophrenia in susceptible individuals.
Indexed as
Identifiers
36204167PMC9507146W4303519567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.